From Nasdaq, Inc.:

Gilead Sciences faced a major drop on the stock exchange after disappointing clinical trial results for its cancer medication, Trodelvy. The phase 3 study did not meet the primary endpoint of overall survival, which was a setback for advanced or metastatic non-small cell lung cancer patients. However, Gilead remains committed to identifying patients who might benefit from the drug and has other avenues to develop it. Investors might be overreacting to the trial results, and Gilead still has opportunity for growth despite the sell-off. The Motley Fool offers investment guidance and does not currently recommend Gilead Sciences as a top stock pick.



Read more: Why Gilead Sciences Stock Got Mashed on Monday